

Development of next-generation allosteric EGFR inhibitor for non-small cell lung cancer treatment

HK inno.N
inno.N

ONCOLOGY	Candidate
Product Type	Small molecule
Indication	EGFR L858R positive NSCLC
Target	EGFR
MoA(Mechanism of Action)	L858R-selective EGFR allosteric inhibitor
Competitiveness	<ul style="list-style-type: none"> • Allosteric EGFR inhibitor could overcome poor responsiveness of L858R mutation and C797S resistant mutation for osimertinib • Potent anti-tumor efficacy in brain metastasis in vivo model • Excellent kinase selectivity and superior EGFR mt selectivity vs. 4th generation ATP competitive EGFR inhibitors • The most potent EGFR inhibitor targeting L858R EGFR mutations including L858R/T790M, L858R/C797S and L858R/T790M/C797S
Development Stage	Candidate
Route of Administration	Oral